The underlying pathophysiological determinants of asthma and COPD are related in complex ways. Importantly however, post-bronchodilator forced expiratory volume in 1 s (FEV1) reversibility may occur in approximately 50% of COPD patients [1], whilst epidemiological [2] and magnetic resonance imaging (MRI) studies [3] suggest that, in asthma patients, FEV1 reversibility may diminish over time. As compared to patients with asthma or COPD alone, patients with co-existing asthma and COPD report worse clinical outcomes [4] and increased healthcare costs [5] and burden [4, 5]. MRI ventilation defect post-bronchodilator reversibility was not always concordant with FEV1 reversibility in asthma and COPD. MRI VDP may provide enhanced sensitivity to small airway response to inhaled medication. http://bit.ly/2qKnwID

中文翻译：

---

FEV1 和 MRI 通气缺陷在哮喘和 COPD 中的可逆性

哮喘和 COPD 的潜在病理生理决定因素以复杂的方式相关。然而，重要的是，大约 50% 的 COPD 患者可能会出现使用支气管扩张剂后 1 秒用力呼气量 (FEV1) 可逆性 [1]，而流行病学[2] 和磁共振成像 (MRI) 研究 [3] 表明，在哮喘患者中患者，FEV1 可逆性可能会随着时间的推移而减弱。与单独患有哮喘或 COPD 的患者相比，同时患有哮喘和 COPD 的患者报告更差的临床结果 [4] 和增加的医疗费用 [5] 和负担 [4, 5]。MRI 通气缺陷后支气管扩张剂可逆性并不总是与哮喘和 COPD 的 FEV1 可逆性一致。MRI VDP 可能会增强对吸入药物的小气道反应的敏感性。http://bit.ly/2qKnwID